Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Comment by wildbird1on Jul 03, 2022 12:56pm
323 Views
Post# 34798078

RE:RE:RE:RE:Dangers of playing the swing trade

RE:RE:RE:RE:Dangers of playing the swing tradeYes I agree the data are confusing...I am not very good at math, but if we read the Pressreleases & Quaterly Newsletters we can find enough data to have a plausible idea of were the CR% could be in Dec 2022 when TLT will make an application for BTD+AA.

From the 3Q2021 Quaterly, we know that 33 patients will have completed 450 days results in Dec, 2022.
18 optimized patients.
+3 patients from Phase1b study.
+12 Phase11 study undertreated patients.
Total= 33 patients.

From the Sept 24, 2020 NewsRelease...
We know that 5 out of 12 undertreated patients have been removed from the phase11 study.
Total  33-5= 28 patients will have completed the 450 days in Dec 2022.
Total=28 Patients.

18 Optimized patients.
From the 3Q2021 Quaterly, we know that the 18 optimized patients have a CR% potential of 94.4%(TLT will never reach that number).
Let's use a big margin of error of 15%.
94.4%-15%=79.4%CR potential
79.4%x 18 patients=14 CR patients.
Total= 14 CR patients/18 optimized patients.

Phase 1b.
Total CR patients= 2CR patients/3 patients.

Undertreated patients.
That leave us with 7 undertreated patients with an unknow CR%..except that from the 3Q2020 Quaterly we know that 3 out of 12 (25%) undertreated patients had a CR.
Meaning..3 out of these 7 undertreated patients have a CR.
Total=3 CR patients/7 undertreated patients.

Grand Total..
14CR+2CR+3CR=19CR patients/28 Patients.

In the 1Q2021 Quaterly, TLT said " Once a patient has achieved a CR, the duration of the CR remain  fairly durable".
19CR patients/28 patients = 70%CR...we have a 450 days plausible 70% CR in Dec 2022.
Considering the very difficult patients that the FDA gave to TLT, anything over 60%CR is huge (50%CR would be more than acceptable).

Note; The 18 optimized patients 360 days CR% results could be very close.

All the above could explain DR.Arkady Mandel in June 21, 2022 PressRelease saying " Impressive preliminary results in the Phase11 NMIBC clinical study". 

Impressive preliminary results.

Time to accumulate.


Rumpl3StiltSkin wrote: Unfortunately most folks are bad at math.

But I do think there are enough good mathematicians(statisticians) that can figure TLT's value after the numbers come in for the ~25. I can imagine after BDT application, which I think TLT will announce by Christmas, those numbers will be crunched by market experts. We will have our SP run up before any monies $$ run out. Of course there are a few here on this board which will also crunch those numbers from every direction. So we'll all know. :-)

I agree it would be nice for average persons to be able to understand the potential here, especially based on the optimized group.

Oilminerdeluxe wrote: Why cant TLT make a table with just optimized patiens and one with both? How hard can it be? I can't be the only one having to guess just what the heck the data means. Maybe things will be much clearer once Roger is back. If he comes back




<< Previous
Bullboard Posts
Next >>